Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration‐Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration
- 14 September 2020
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 61 (3) , 328-338
Abstract
Valganciclovir (VGCV) is the prodrug of ganciclovir (GCV). The objective of this study was to establish a population pharmacokinetic model (PPK) of GCV to investigate the PK characteristics of GCV after administration of VGCV in adult Chinese renal allograft recipients. Seventy Chinese renal allograft recipients were given 450 mg (n = 41) or 900 mg (n = 29) VGCV daily. Blood samples were drawn 0‐24 hours after 5 days’ therapy, and GCV plasma levels were determined. The PPK model was constructed using nonlinear mixed‐effects modeling, and the Bayesian estimation of AUC0‐24h was constructed for an individual patient based on limited plasma samples. The PK of GCV was best described by a 2‐compartment model with a first‐order absorption process. The CL/F, V2/F, Q/F, V3/F, Ka, and lag time of GCV were 15.8 ± 0.71 L/h, 10.9 ± 2.38 L, 3.98 ± 0.40 L/h, 167 ± 44.0 L, 0.23 ± 0.0078 1/h, and 0.93 ± 0.017 hours, respectively. Clearance of creatinine was found to have a significant impact on the CL/F of GCV (P < .01). Sampling strategies consisted of plasma concentrations 0 and 2 and 0, 2, and 4 hours after VGCV administration were shown to be suitable for the estimation of the GCV AUC0‐24h. The PPK model was acceptable and can describe the PK of GCV in Chinese renal transplant patients administered VGCV. The AUC0‐24h of GCV in Chinese renal transplant patients can be calculated by a limited sampling strategy method.Keywords
Funding Information
- National Natural Science Foundation of China (81473275, 81973387)
This publication has 36 references indexed in Scilit:
- Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality riskClinical Transplantation, 2007
- Seroprevalence of Cytomegalovirus Infection in the United States, 1988-1994Clinical Infectious Diseases, 2006
- Association of Cytomegalovirus Disease and Acute Rejection with Graft Loss in Kidney TransplantationTransplantation, 2004
- Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantationDiabetologia, 2004
- Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survivalKidney International, 2004
- The Impact of Cytomegalovirus Infection and Disease on Rejection Episodes in Renal Allograft RecipientsAmerican Journal of Transplantation, 2002
- Preemptive Therapy Versus Universal Prophylaxis with Ganciclovir for Cytomegalovirus in Solid Organ Transplant RecipientsClinical Infectious Diseases, 2001
- A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1Transplantation, 2000
- Infection in Organ-Transplant RecipientsNew England Journal of Medicine, 1998
- CYTOMEGALOVIRUS INFECTION—AN ETIOLOGICAL FACTOR FOR REJECTION? A PROSPECTIVE STUDY IN 242 RENAL TRANSPLANT PATIENTSTransplantation, 1993